Centessa's OX2R agonist pipeline includes a potential best-in-class therapeutic with significant promise to meaningfully improve outcomes across a range of sleep-wake disorders Acquisition expands Lilly's neuroscience portfolio and capabilities into sleep medicine INDIANAPOLIS and BOSTON and
BOSTON and LONDON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following
Antidepressive effects and enhanced wakefulness were observed with OX2R activation in established animal model of major depressive disorder BOSTON and LONDON, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on developing
